10 Best Biotech Stocks to Buy Under $10

Page 9 of 9

1. Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Number of Hedge Fund Holders: 40 

Share Price: $7.40 

Amicus Therapeutics, Inc. (NASDAQ:FOLD) tops our list for being one of the best biotech stocks. It develops therapies for rare diseases, including Fabry disease and late-onset Pompe disease. Its flagship products include Galafold, an oral precision medicine for Fabry disease, and the combination therapy Pombiliti + Opfolda for Pompe disease.

The company recently acquired DMX-200, a candidate targeting focal segmental glomerulosclerosis (FSGS), broadening its rare disease portfolio and strengthening long-term growth potential beyond current products. This expansion enhances diversification and mitigates risks associated with portfolio concentration.

Despite a year-over-year net loss in Q2 2025, Amicus Therapeutics, Inc. (NASDAQ:FOLD) reaffirmed guidance for 15–22% total revenue growth and anticipates positive GAAP net income in the second half of 2025. Strong sales traction for Galafold and growing adoption of Pombiliti + Opfolda are key drivers of this revenue growth.

Analysts remain positive on Amicus Therapeutics, Inc. (NASDAQ:FOLD), with price targets between $13 and $20, reflecting potential upside from its expanding rare disease franchise, pipeline development, and improving profitability. Firms like TD Cowen and Guggenheim maintain Buy ratings, highlighting the corporation’s strategic positioning and growth prospects.

While we acknowledge the potential of FOLD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than FOLD and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9